EPZ015666 is a selective PRMT5 inhibitor that binds to the peptide-binding site, giving the compound a peptide-competitive and SAM-uncompetitive characteristic, and its antitumor role has been tested in several cancer cell lines [4,23,24,25]. The gene discussed is PRMT5; the disease is cancer.